Articles

Podcasts

Videos

Clinical

Compared to fidaxomicin and vancomycinfecal, microbiota transplant (FMT) was the most cost-effective treatment for first and subsequent recurrent C difficile infection.

FMT Cost-Effective for 90% of Recurrent C Difficile Infections

 Frequent recurrence of Clostridioides difficile infection drives up financial burdens of the disease and underscores the need to improve access to treatment, infection prevention, and new therapies.

Recurrence Escalates Financial Burden of CDI

Hospitalization rates increased significantly after sepsis, with 11.9% of survivors rehospitalized for recurrent sepsis, and 56.6% receiving outpatient anti-infective treatment.

Hospitalizations and Drug Prescriptions in Patients Pre- and Post-Sepsis

Eric Shaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.

New Therapeutic Repopulates the Gut Microbiome to Prevent Recurrent C Diff Infection

People exposed to a family member recently hospitalized with C difficile infection were 73% more likely to contract CDI themselves.

Hospitalized C Diff Patients May Pass Infection to Family

SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.

Investigational Microbiome Therapeutic SER-109 Reduces C Difficile Recurrence

Investigators performed a systematic review to assess just how strong the association between race and urinary tract infections (UTIs) in children.

Pediatric UTI Risk Assessments and Race 

About 65% of patients with metronidazole-resistant recurrent C difficile infection benefitted from taking rifaximin.

Rifaximin Effective in Majority of Patients Recurrent CDI Who Do Not Respond to Metronidazole

Entasis Therapeutics gave 2 oral presentations at ECCMID today detailing results of their ATTACK trial, investigating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) for multidrug-resistant pathogens.

Novel Antibiotics for Resistant Pathogens: Results of ATTACK Trial for Sulbactam-Durlobactam

During the pandemic, antibiotic-resistant bacterial infections increased in hospitalized patients who tested positive or negative for COVID-19.

HEALTHCARE-ASSOCIATED INFECTIONS (HAI)

Latest News